The National Institutes of Health (NIH) Clinical Center intends to award a sole-source firm-fixed-price purchase order to Fisher Scientific for validated reagents and consumable materials used in FDA-regulated cell therapy manufacturing. These materials are required by the Center for Cellular Engineering (CCE) for patient clinical trials and have been approved by CCE Quality Assurance. Substituting alternative products would require extensive revalidation, increase costs, delay production, and potentially impact patient care. Performance will occur at the NIH Clinical Center in Bethesda, MD. This notice is for information purposes only; responsible sources may submit a capability statement for consideration.